OGN vs RYN · P/E 3.4, rev $3.02B vs P/E 45, rev $484.5M
Organon & Co (OGN) versus Rayonier Inc (RYN) — a side-by-side from cached financials, not a winner call.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Rayonier Inc (RYN) is a reit - specialty company listed on NYSE.
Latest reported OGN revenue for 2026-06-30 was $3.02B. Net income was $254.0M. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Latest reported RYN revenue for 2025-12-31 was $484.5M. Net income was $474.4M. Revenue was down 61.6% from 2024-12-31 to 2025-12-31. RYN currently screens at market cap $6.27B and trailing P/E 45.1.
OGN currently screens at market cap $2.52B and trailing P/E 3.4. RYN currently screens at market cap $6.27B and trailing P/E 45.1.
Not investment advice. Open the OGN and RYN stock pages for the full models.
Not investment advice.